![shaverdashvili full page](/sites/default/files/styles/resource_image/public/2023-09/shaverdashvili%20full%20page.png?itok=lID3tm-L)
Download
(1.32 MB)
General
Metastatic NSCLC with ROS1 Rearrangement and Multiple Acquired Resistance Mechanisms to Tyrosine Kinase Inhibitor Therapy: Chasing the Target
Khvaramze Shaverdashvili, MD
Timothy F. Burns, MD, PhD
United States